130 related articles for article (PubMed ID: 32889748)
1. Quercetin and hydroxytyrosol as modulators of hepatic steatosis: A NAFLD-on-a-chip study.
Gori M; Giannitelli SM; Zancla A; Mozetic P; Trombetta M; Merendino N; Rainer A
Biotechnol Bioeng; 2021 Jan; 118(1):142-152. PubMed ID: 32889748
[TBL] [Abstract][Full Text] [Related]
2. Investigating Nonalcoholic Fatty Liver Disease in a Liver-on-a-Chip Microfluidic Device.
Gori M; Simonelli MC; Giannitelli SM; Businaro L; Trombetta M; Rainer A
PLoS One; 2016; 11(7):e0159729. PubMed ID: 27438262
[TBL] [Abstract][Full Text] [Related]
3. The Antioxidant Effects of Hydroxytyrosol and Vitamin E on Pediatric Nonalcoholic Fatty Liver Disease, in a Clinical Trial: A New Treatment?
Nobili V; Alisi A; Mosca A; Crudele A; Zaffina S; Denaro M; Smeriglio A; Trombetta D
Antioxid Redox Signal; 2019 Jul; 31(2):127-133. PubMed ID: 30588836
[TBL] [Abstract][Full Text] [Related]
4. A Human Liver-on-a-Chip Platform for Modeling Nonalcoholic Fatty Liver Disease.
Lasli S; Kim HJ; Lee K; Suurmond CE; Goudie M; Bandaru P; Sun W; Zhang S; Zhang N; Ahadian S; Dokmeci MR; Lee J; Khademhosseini A
Adv Biosyst; 2019 Aug; 3(8):e1900104. PubMed ID: 32648699
[TBL] [Abstract][Full Text] [Related]
5. Nano-encapsulation of hydroxytyrosol into formulated nanogels improves therapeutic effects against hepatic steatosis: An in vitro study.
Mauri E; Gori M; Giannitelli SM; Zancla A; Mozetic P; Abbruzzese F; Merendino N; Gigli G; Rossi F; Trombetta M; Rainer A
Mater Sci Eng C Mater Biol Appl; 2021 May; 124():112080. PubMed ID: 33947572
[TBL] [Abstract][Full Text] [Related]
6. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
[TBL] [Abstract][Full Text] [Related]
7. Modeling nonalcoholic fatty liver disease on a liver lobule chip with dual blood supply.
Du K; Li S; Li C; Li P; Miao C; Luo T; Qiu B; Ding W
Acta Biomater; 2021 Oct; 134():228-239. PubMed ID: 34265474
[TBL] [Abstract][Full Text] [Related]
8. Modeling Human Nonalcoholic Fatty Liver Disease (NAFLD) with an Organoids-on-a-Chip System.
Wang Y; Wang H; Deng P; Tao T; Liu H; Wu S; Chen W; Qin J
ACS Biomater Sci Eng; 2020 Oct; 6(10):5734-5743. PubMed ID: 33320545
[TBL] [Abstract][Full Text] [Related]
9. Phytotherapy using blueberry leaf polyphenols to alleviate non-alcoholic fatty liver disease through improving mitochondrial function and oxidative defense.
Li Z; Zhang H; Li Y; Chen H; Wang C; Wong VKW; Jiang Z; Zhang W
Phytomedicine; 2020 Apr; 69():153209. PubMed ID: 32240928
[TBL] [Abstract][Full Text] [Related]
10. Hydroxytyrosol prevents metabolic impairment reducing hepatic inflammation and restoring duodenal integrity in a rat model of NAFLD.
Pirozzi C; Lama A; Simeoli R; Paciello O; Pagano TB; Mollica MP; Di Guida F; Russo R; Magliocca S; Canani RB; Raso GM; Calignano A; Meli R
J Nutr Biochem; 2016 Apr; 30():108-15. PubMed ID: 27012627
[TBL] [Abstract][Full Text] [Related]
11. Psoralea corylifolia L. extract ameliorates nonalcoholic fatty liver disease in free-fatty-acid-incubated HEPG2 cells and in high-fat diet-fed mice.
Hong Y; Choi SI; Hong E; Kim GH
J Food Sci; 2020 Jul; 85(7):2216-2226. PubMed ID: 32579753
[TBL] [Abstract][Full Text] [Related]
12. Procyanidin B2 ameliorates free fatty acids-induced hepatic steatosis through regulating TFEB-mediated lysosomal pathway and redox state.
Su H; Li Y; Hu D; Xie L; Ke H; Zheng X; Chen W
Free Radic Biol Med; 2018 Oct; 126():269-286. PubMed ID: 30142454
[TBL] [Abstract][Full Text] [Related]
13. In vitro hepatic steatosis model based on gut-liver-on-a-chip.
Jeon JW; Lee SH; Kim D; Sung JH
Biotechnol Prog; 2021 May; 37(3):e3121. PubMed ID: 33393209
[TBL] [Abstract][Full Text] [Related]
14. Molecular adaptations underlying the beneficial effects of hydroxytyrosol in the pathogenic alterations induced by a high-fat diet in mouse liver: PPAR-α and Nrf2 activation, and NF-κB down-regulation.
Valenzuela R; Illesca P; Echeverría F; Espinosa A; Rincón-Cervera MÁ; Ortiz M; Hernandez-Rodas MC; Valenzuela A; Videla LA
Food Funct; 2017 Apr; 8(4):1526-1537. PubMed ID: 28386616
[TBL] [Abstract][Full Text] [Related]
15. Hepatic STAMP2 mediates recombinant FGF21-induced improvement of hepatic iron overload in nonalcoholic fatty liver disease.
Kim HY; Kwon WY; Park JB; Lee MH; Oh YJ; Suh S; Baek YH; Jeong JS; Yoo YH
FASEB J; 2020 Sep; 34(9):12354-12366. PubMed ID: 32721044
[TBL] [Abstract][Full Text] [Related]
16. Attenuation of High-Fat Diet-Induced Rat Liver Oxidative Stress and Steatosis by Combined Hydroxytyrosol- (HT-) Eicosapentaenoic Acid Supplementation Mainly Relies on HT.
Echeverría F; Valenzuela R; Bustamante A; Álvarez D; Ortiz M; Soto-Alarcon SA; Muñoz P; Corbari A; Videla LA
Oxid Med Cell Longev; 2018; 2018():5109503. PubMed ID: 30057681
[TBL] [Abstract][Full Text] [Related]
17. Lipid-lowering agents inhibit hepatic steatosis in a non-alcoholic steatohepatitis-derived hepatocellular carcinoma mouse model.
Orime K; Shirakawa J; Togashi Y; Tajima K; Inoue H; Nagashima Y; Terauchi Y
Eur J Pharmacol; 2016 Feb; 772():22-32. PubMed ID: 26724391
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib reduces steatosis-induced fibrogenesis in a human 3D co-culture model of non-alcoholic fatty liver disease.
Romualdo GR; Da Silva TC; de Albuquerque Landi MF; Morais JÁ; Barbisan LF; Vinken M; Oliveira CP; Cogliati B
Environ Toxicol; 2021 Feb; 36(2):168-176. PubMed ID: 32918399
[TBL] [Abstract][Full Text] [Related]
19. Metabolomics Characterizes the Effects and Mechanisms of Quercetin in Nonalcoholic Fatty Liver Disease Development.
Xu Y; Han J; Dong J; Fan X; Cai Y; Li J; Wang T; Zhou J; Shang J
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30862046
[TBL] [Abstract][Full Text] [Related]
20. [Effect of quercetin on morphological changes in nonalcoholic fatty liver disease in high fructose-fed rats].
Nikitin NS; Kuznetsov SL
Vopr Pitan; 2018; 87(6):16-21. PubMed ID: 30763486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
